Jonathan L. Halperin

Jonathan L. Halperin


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MKMonika Kozieł-Siołkowska
Monika Kozieł-Siołkowska
MMMichał Mazurek
Michał Mazurek
CTChristine Teutsch
Christine Teutsch
HDHans-Christoph Diener
Hans-Christoph Diener
SDSergio Dubner
Sergio Dubner
Gregory LipGregory Lip
Gregory Lip
Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)). Methods: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy. Results: Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence. Conclusions: Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.

1 November 2012 in Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
Verified
Journal Article
Closed access
PDF file
JHJonathan L. Halperin
Jonathan L. Halperin
RGRichert E. Goyette
Richert E. Goyette

7 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
Elena GhotbiElena Ghotbi
Elena Ghotbi
NSNikhil Subhas
Nikhil Subhas
MBMichael Bancks
Michael Bancks
SESammy Elmariah
Sammy Elmariah
JHJonathan L. Halperin
Jonathan L. Halperin
SDShadpour Demehri
Shadpour Demehri
Background/Objectives: Bisphosphonates may influence vascular calcification and atheroma formation via farnesyl pyrophosphate synthase inhibition in the mevalonate pathway regulating bone and lipid metabolism. However, the clinical impact of NCB use on cardiovascular outcomes remains uncertain, largely due to methodological heterogeneity in prior studies. We aimed to evaluate the association between nitrogen-containing bisphosphonate (NCB) therapy and coronary artery calcium (CAC) progression, as well as the incidence of cardiovascular disease (CVD) and coronary heart disease (CHD) events. Methods: From 6814 participants in MESA Exam 1, we excluded males (insufficient male NCB users in the MESA cohort), pre-menopausal women, baseline NCB users, and users of hormone replacement therapy, raloxifene, or calcitonin. Among 166 NCB initiators and 1571 non-users with available CAC measurements, propensity score matching was performed using the available components of FRAX, namely age, race, BMI, LDL cholesterol, alcohol, smoking, and steroid use, and baseline CAC yielded 165 NCB initiators matched to 473 non-users (1:3 ratio). Linear mixed-effects models evaluated CAC progression, and Cox models analyzed incident CVD and CHD events. Results: In the overall cohort, NCB use was not significantly associated with CAC progression (annual change: −0.01 log Agatston units; 95% CI: −0.05 to 0.01). However, among participants with a baseline estimated glomerular filtration rate (eGFR) < 65 mL/min/1.73 m2, NCB use was associated with attenuated CAC progression compared with non-users (−0.06 log Agatston units/year; 95% CI: −0.12 to −0.007). No significant association was observed between NCB use and incident CVD events in the overall cohort (HR: 0.90; 95% CI: 0.60−1.36) or within kidney function subgroups. Conclusions: Incident NCB use among postmenopausal women with mild or no CAC at baseline was associated with reduced CAC progression only in women with impaired kidney function. However, this association did not correspond to a decreased risk of subsequent cardiovascular events, suggesting that the observed imaging benefit may not translate into meaningful clinical association.

7 December 2018 in Science
Verified
Journal Article
Closed access
PDF file
JHJonathan L. Halperin
Jonathan L. Halperin

29 April 2023 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MSMohan Satish
Mohan Satish
RWRyan W. Walters
Ryan W. Walters
VAVenkata M. Alla
Venkata M. Alla
JHJonathan L. Halperin
Jonathan L. Halperin